Combination use of novel lactobacillus plantarum strain and strain-derived polysaccharide for preventing or treating tumors

Abstract

The present invention relates to a combination use of a novel Lactobacillus plantarum IMB19 strain and/or polysaccharides derived from the strain with an anticancer drug for preventing or treating tumors. The novel Lactobacillus plantarum IMB19 strain and polysaccharides derived from the strain of the present invention exhibit an excellent ability to stimulate CD8+T cell activity and exhibit excellent Treg cell inhibitory activity, and stimulate and improve antitumor immune response through various mechanisms such as increased macrophage infiltration in CPS tumors and differentiation and reprogramming of macrophages into an inflammatory phenotype (M1). Furthermore, the strain and the polysaccharides may significantly increase antitumor immune response when administered in combination with an anticancer drug, particularly an immuno-anticancer drug such as a PD-1 or PD-L1 inhibitor (e.g., a PD-1 antibody, a PD-L1 antibody, or the like), and exhibit a remarkable tumor growth suppression effect compared to the case of using the anticancer drug alone. Therefore, the present invention can be effectively used to prevent, relieve, or treat tumors through administration in combination with various anticancer drugs.

Dependencies are inferred from the claim text.